Teachers Advisors LLC cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 7.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 77,093 shares of the medical instruments supplier’s stock after selling 6,094 shares during the period. Teachers Advisors LLC’s holdings in AngioDynamics were worth $1,338,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ANGO. Ameriprise Financial Inc. raised its stake in AngioDynamics by 22.4% in the first quarter. Ameriprise Financial Inc. now owns 614,721 shares of the medical instruments supplier’s stock valued at $10,666,000 after buying an additional 112,693 shares during the period. Bank of New York Mellon Corp raised its stake in AngioDynamics by 4.5% in the first quarter. Bank of New York Mellon Corp now owns 495,099 shares of the medical instruments supplier’s stock valued at $8,591,000 after buying an additional 21,277 shares during the period. Russell Investments Group Ltd. raised its stake in AngioDynamics by 5.7% in the first quarter. Russell Investments Group Ltd. now owns 315,863 shares of the medical instruments supplier’s stock valued at $5,480,000 after buying an additional 17,044 shares during the period. American Century Companies Inc. raised its stake in AngioDynamics by 65.9% in the first quarter. American Century Companies Inc. now owns 297,659 shares of the medical instruments supplier’s stock valued at $5,164,000 after buying an additional 118,250 shares during the period. Finally, Prudential Financial Inc. raised its stake in AngioDynamics by 26.7% in the first quarter. Prudential Financial Inc. now owns 290,991 shares of the medical instruments supplier’s stock valued at $5,049,000 after buying an additional 61,340 shares during the period. Hedge funds and other institutional investors own 95.80% of the company’s stock.

Shares of AngioDynamics, Inc. (ANGO) traded up 0.3651% on Monday, reaching $16.5201. 20,764 shares of the company traded hands. The company has a 50-day moving average of $16.36 and a 200-day moving average of $16.20. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.18. The stock has a market capitalization of $604.31 million, a price-to-earnings ratio of 120.5847 and a beta of 1.15.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. During the same period last year, the firm posted $0.19 EPS. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. Analysts anticipate that AngioDynamics, Inc. will post $0.67 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://theolympiareport.com/2017/08/28/teachers-advisors-llc-has-1-34-million-stake-in-angiodynamics-inc-ango.html.

ANGO has been the subject of several analyst reports. BidaskClub upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Barclays PLC reduced their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a report on Friday. Finally, Cantor Fitzgerald upped their target price on shares of AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $18.50.

In other AngioDynamics news, CEO James C. Clemmer bought 5,000 shares of the company’s stock in a transaction on Friday, July 21st. The stock was purchased at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were acquired at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock valued at $396,806 over the last 90 days. 1.88% of the stock is currently owned by insiders.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.